Related Experiment Video

Updated: Jul 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5

Sashi Kesavapany1, Ya-Li Zheng, Niranjana Amin

  • 1Yong Loo Lin School of Medicine, Department of Biochemistry, Singapore, Singapore.

Biotechnology Journal
|May 26, 2007
PubMed

Insights

A novel Cdk5 inhibitory peptide (CIP) selectively targets the neurotoxic p25/Cdk5 complex, reducing tau hyperphosphorylation and neuronal death. This offers a potential therapeutic strategy for neurodegenerative diseases like Alzheimer's.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Cyclin-dependent kinase 5 (Cdk5) activity is crucial for neuronal function.
  • Aberrant Cdk5 activation by p25, a cleavage product of p35, is implicated in neurodegenerative diseases.
  • Elevated p25 levels and associated pathologies are observed in Alzheimer's disease (AD) brains.

Purpose of the Study:

  • To investigate selective inhibition of the neurotoxic p25/Cdk5 complex.
  • To explore the therapeutic potential of targeting p25/Cdk5 in neurodegeneration.

Main Methods:

  • Truncation of p25 to create a Cdk5 inhibitory peptide (CIP).
  • Testing CIP's inhibitory effect on p25/Cdk5 activity in HEK cells and primary cortical neurons.
  • Evaluating CIP's impact on tau hyperphosphorylation and p25/Cdk5-induced neuronal death.

Main Results:

  • CIP specifically inhibits p25/Cdk5 activity without affecting p35/Cdk5 or mitotic Cdk activities.
  • CIP treatment reduced tau hyperphosphorylation and neuronal death in cellular models.
  • The findings demonstrate selective targeting of the aberrant p25/Cdk5 pathway.

Conclusions:

  • A Cdk5 inhibitory peptide (CIP) offers a promising strategy for selective inhibition of p25/Cdk5.
  • CIP may serve as a therapeutic agent for neurodegenerative conditions characterized by p25/Cdk5 dysregulation.
  • Further research into CIP could lead to novel treatments for Alzheimer's disease and other neurotoxic disorders.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.